Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xeris Pharmaceuticals Inc

4.82
+0.26005.70%
Post-market: 4.80-0.0200-0.41%19:47 EDT
Volume:6.61M
Turnover:31.47M
Market Cap:741.99M
PE:-12.90
High:4.90
Open:4.59
Low:4.50
Close:4.56
Loading ...

Xeris Biopharma Is Maintained at Buy by Craig-Hallum

Dow Jones
·
10 Mar

Xeris Biopharma price target raised to $6 from $5 at Leerink

TIPRANKS
·
08 Mar

Stock Track | Xeris Pharmaceuticals Soars 5.33% as Analysts Raise Price Targets

Stock Track
·
07 Mar

Xeris Biopharma price target raised to $4 from $3 at Piper Sandler

TIPRANKS
·
07 Mar

Xeris Biopharma Price Target Raised to $8.00/Share From $6.60 by HC Wainwright & Co.

Dow Jones
·
07 Mar

Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright

TIPRANKS
·
07 Mar

Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...

GuruFocus.com
·
07 Mar

Xeris Biopharma files $250M mixed securities shelf

TIPRANKS
·
07 Mar

Xeris Biopharma Shares Rise on Expectation of Significant Full-Year Revenue Growth

Dow Jones
·
07 Mar

Stock Track | Xeris Pharmaceuticals Soars 9.81% on Record Q4 Results and Strong 2025 Outlook

Stock Track
·
06 Mar

Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

Zacks
·
06 Mar

Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
06 Mar

Stock Track | Xeris Pharmaceuticals (XERS) Soars 5.16% Pre-market on Record Q4 Results, Strong 2025 Outlook

Stock Track
·
06 Mar

Xeris Biopharma: Q4 Earnings Snapshot

Associated Press Finance
·
06 Mar

Xeris Biopharma Expects 2025 Revenue Of $255M-$275M, Representing Growth Of Over 30% At The Mid-point Of The Range Versus Consensus Of $239.84M

Benzinga
·
06 Mar